| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| TAEST-1901 | TAEST-1901 | Phase 2 Clinical | Xiangxue Life Science Technology (Guangdong) Co Ltd | Liver Neoplasms; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| JWATM-203 | JWATM-203; JWATM203 | Phase 2 Clinical | Suzhou Yaomingjunuo Biotechnology Co Ltd | Carcinoma, Hepatocellular | Details |
| SynOV1.1 | SynOV1.1 | Phase 2 Clinical | Beijing Syngentech Co Ltd | Carcinoma, Hepatocellular; Solid tumours | Details |
| ET140203 | Phase 2 Clinical | Eureka Therapeutics Inc | Carcinoma, Hepatocellular; Hepatoblastoma; Liver Neoplasms | Details | |
| CPU-118 | CPU-118 | Phase 2 Clinical | China Pharmaceutical University, Nanjing Qinling Pharmaceutical Technology Co Ltd | Liver Neoplasms; Neoplasms; Solid tumours | Details |
| Alpha fetoprotein targeted T-cell therapy (Adaptimmune) | AFP TCR (ADP-A2AFP); ADP-A2AFP; AFP TCR; AFPc332T | Phase 1 Clinical | Adaptimmune Llc | Carcinoma, Hepatocellular | Details |